about
Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1.HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.Molecular switch of EZH2 in hypoxia.Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma.Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence.MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival.Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategyHypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancerKDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast CancerMethionine is a metabolic dependency of tumor-initiating cellsKDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancerHER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatmentGut stem cell aging is driven by mTORC1 via a p38 MAPK-p53 pathway
P50
Q34031684-7F151997-5001-4E72-84AA-72B88F5C179AQ37065194-EB832C86-7C8E-48A8-89CC-B0D7FFDDC60FQ37467595-E9ECB43C-6977-4BC1-9C34-2A5BCB8F0DE4Q38705350-AE1ED152-E57A-4644-B49C-9BDF1FAB10ACQ38764673-037E337F-873A-453E-B2E2-8A08A1C2B78CQ38941996-00494DD3-5E89-486C-AD68-2F515EB81210Q38982261-86289272-C57E-47A2-A1F4-BFB432C39C19Q40046777-5ECBE7C7-DC64-4280-903C-C52A58F9AE83Q45964566-A088A3DD-C4FD-42A6-BF11-167FAA0ADEC8Q45990980-ECBB42BF-81C8-44BB-A602-4CEB027E27C1Q47350725-FD678D1D-D120-4555-8162-B11A35E56CA0Q57116991-CD770F08-98ED-4C89-89D1-ECE4312D042DQ89068921-8FDE7D07-ED1E-4490-9204-16AB141CBB10Q89169509-5B0E65D9-ADF7-4F51-8EE7-4C4D1EA49554Q91806615-8C29FA79-E642-4BD9-8BC4-66DF0143E011Q91859346-D5BFAC1B-99A1-4B55-AB24-3E25E52E120FQ92335678-B1B2B23A-51E9-410A-A537-4C0A3EDEE247Q92380598-655BD83D-DACB-4C81-940F-649A3889EC67
P50
description
researcher (ORCID 0000-0003-2132-8278)
@en
name
Qiang Yu
@en
type
label
Qiang Yu
@en
prefLabel
Qiang Yu
@en
P108
P31
P496
0000-0003-2132-8278